Terms: = Endocrine gland cancer AND FANCD2, FANCD, 2177, ENSG00000144554, FLJ23826, FAD, FACD, FA4, FA-D2, FAD2, DKFZp762A223 AND Treatment
23 results:
1. Preomic profile of BxPC-3 cells after treatment with BRC4.
Previtali V; Myers SH; Poppi L; Wynne K; Casamassima I; Girotto S; Di Stefano G; Farabegoli F; Roberti M; Oliviero G; Cavalli A
J Proteomics; 2023 Sep; 288():104983. PubMed ID: 37536521
[TBL] [Abstract] [Full Text] [Related]
2. DOSE RELATIONSHIP DURING RADIOABLATION OF THYROID RESIDUAL IN PATIENTS WITH THYROID DIFFERENTIATED cancer.
Dzhuzha DO
Probl Radiac Med Radiobiol; 2022 Dec; 27():431-439. PubMed ID: 36582107
[TBL] [Abstract] [Full Text] [Related]
3. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
Lu Z; Mao W; Yang H; Santiago-O'Farrill JM; Rask PJ; Mondal J; Chen H; Ivan C; Liu X; Liu CG; Xi Y; Masuda K; Carrami EM; Chen M; Tang Y; Pang L; Lakomy DS; Calin GA; Liang H; Ahmed AA; Vankayalapati H; Bast RC
J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35642638
[TBL] [Abstract] [Full Text] [Related]
4. A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene.
Fierheller CT; Guitton-Sert L; Alenezi WM; Revil T; Oros KK; Gao Y; Bedard K; Arcand SL; Serruya C; Behl S; Meunier L; Fleury H; Fewings E; Subramanian DN; Nadaf J; Bruce JP; Bell R; Provencher D; Foulkes WD; El Haffaf Z; Mes-Masson AM; Majewski J; Pugh TJ; Tischkowitz M; James PA; Campbell IG; Greenwood CMT; Ragoussis J; Masson JY; Tonin PN
Genome Med; 2021 Dec; 13(1):186. PubMed ID: 34861889
[TBL] [Abstract] [Full Text] [Related]
5. Hedgehog/GLI1 Transcriptionally Regulates fancd2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
Mani C; Tripathi K; Chaudhary S; Somasagara RR; Rocconi RP; Crasto C; Reedy M; Athar M; Palle K
Neoplasia; 2021 Sep; 23(9):1002-1015. PubMed ID: 34380074
[TBL] [Abstract] [Full Text] [Related]
6. Progesterone induces apoptosis by activation of caspase-8 and calcitriol via activation of caspase-9 pathways in ovarian and endometrial cancer cells in vitro.
McGlorthan L; Paucarmayta A; Casablanca Y; Maxwell GL; Syed V
Apoptosis; 2021 Apr; 26(3-4):184-194. PubMed ID: 33515314
[TBL] [Abstract] [Full Text] [Related]
7. Identification of Hub Genes in High-Grade Serous Ovarian cancer Using Weighted Gene Co-Expression Network Analysis.
Wu M; Sun Y; Wu J; Liu G
Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
[TBL] [Abstract] [Full Text] [Related]
8. [Stereotactic body radiotherapy: Passing fad or revolution?].
Vallard A; Vial N; Jmour O; Rehailia-Blanchard A; Trone JC; Sotton S; Daguenet E; Guy JB; Magné N
Bull Cancer; 2020 Feb; 107(2):244-253. PubMed ID: 31864665
[TBL] [Abstract] [Full Text] [Related]
9. CRL4 ubiquitin ligase stimulates Fanconi anemia pathway-induced single-stranded DNA-RPA signaling.
Codilupi T; Taube D; Naegeli H
BMC Cancer; 2019 Nov; 19(1):1042. PubMed ID: 31690264
[TBL] [Abstract] [Full Text] [Related]
10. Clinical importance of fancd2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas.
Moes-Sosnowska J; Rzepecka IK; Chodzynska J; Dansonka-Mieszkowska A; Szafron LM; Balabas A; Lotocka R; Sobiczewski P; Kupryjanczyk J
Cancer Biol Ther; 2019; 20(6):843-854. PubMed ID: 30822218
[TBL] [Abstract] [Full Text] [Related]
11. Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection.
Gleeson FC; Kerr SE; Kipp BR; Voss JS; Minot DM; Tu ZJ; Henry MR; Graham RP; Vasmatzis G; Cheville JC; Lazaridis KN; Levy MJ
Oncotarget; 2016 Aug; 7(34):54526-54536. PubMed ID: 27203738
[TBL] [Abstract] [Full Text] [Related]
12. Genomic and transcriptomic plasticity in treatment-naive ovarian cancer.
Hoogstraat M; de Pagter MS; Cirkel GA; van Roosmalen MJ; Harkins TT; Duran K; Kreeftmeijer J; Renkens I; Witteveen PO; Lee CC; Nijman IJ; Guy T; van 't Slot R; Jonges TN; Lolkema MP; Koudijs MJ; Zweemer RP; Voest EE; Cuppen E; Kloosterman WP
Genome Res; 2014 Feb; 24(2):200-11. PubMed ID: 24221193
[TBL] [Abstract] [Full Text] [Related]
13. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer.
Colombo PE; Fabbro M; Theillet C; Bibeau F; Rouanet P; Ray-Coquard I
Crit Rev Oncol Hematol; 2014 Feb; 89(2):207-16. PubMed ID: 24071502
[TBL] [Abstract] [Full Text] [Related]
14. Gossypol induces apoptosis in ovarian cancer cells through oxidative stress.
Wang J; Jin L; Li X; Deng H; Chen Y; Lian Q; Ge R; Deng H
Mol Biosyst; 2013 Jun; 9(6):1489-97. PubMed ID: 23532321
[TBL] [Abstract] [Full Text] [Related]
15. RNA interference-mediated FANCF silencing sensitizes OVCAR3 ovarian cancer cells to adriamycin through increased adriamycin-induced apoptosis dependent on JNK activation.
He M; Sun HG; Hao JY; Li YL; Yu JK; Yan YY; Zhao L; Li N; Wang Y; Bai XF; Yu ZJ; Zheng ZH; Mi XY; Wang EH; Wei MJ
Oncol Rep; 2013 May; 29(5):1721-9. PubMed ID: 23440494
[TBL] [Abstract] [Full Text] [Related]
16. Assessment of fancd2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.
Duan W; Gao L; Zhao W; Leon M; Sadee W; Webb A; Resnick K; Wu X; Ramaswamy B; Cohn DE; Shapiro C; Andreassen PR; Otterson GA; Villalona-Calero MA
Transl Res; 2013 Mar; 161(3):156-64. PubMed ID: 23063585
[TBL] [Abstract] [Full Text] [Related]
17. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.
Jacquemont C; Simon JA; D'Andrea AD; Taniguchi T
Mol Cancer; 2012 Apr; 11():26. PubMed ID: 22537224
[TBL] [Abstract] [Full Text] [Related]
18. BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
Wysham WZ; Mhawech-Fauceglia P; Li H; Hays L; Syriac S; Skrepnik T; Wright J; Pande N; Hoatlin M; Pejovic T
PLoS One; 2012; 7(1):e30042. PubMed ID: 22253870
[TBL] [Abstract] [Full Text] [Related]
19. Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray.
Morse DL; Balagurunathan Y; Hostetter G; Trissal M; Tafreshi NK; Burke N; Lloyd M; Enkemann S; Coppola D; Hruby VJ; Gillies RJ; Han H
Biochem Pharmacol; 2010 Sep; 80(5):748-54. PubMed ID: 20510208
[TBL] [Abstract] [Full Text] [Related]
20. Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
Chung TT; Evanson J; Walker D; Akker SA; Besser GM; Monson JP; Grossman AB; Drake WM
Clin Endocrinol (Oxf); 2008 Jun; 68(6):965-9. PubMed ID: 18031317
[TBL] [Abstract] [Full Text] [Related]
[Next]
